USV, a Mumbai-based pharmaceutical company, announced on Thursday that it had successfully completed phase 1 and phase 3 studies on a proposed pegfilgrastim biosimilar referenced on Neulasta. The company expects to submit data for its marketing authorization application to the European Medicines Agency before the end of 2017.
USV, a Mumbai-based pharmaceutical company, announced on Thursday that it had successfully completed phase 1 and phase 3 studies on a proposed pegfilgrastim biosimilar referenced on Neulasta. The company expects to submit data for its marketing authorization application to the European Medicines Agency before the end of 2017.
The phase 1 studies, which compared the pharmacokinetics and pharmacodynamics of the biosimilar with the reference product at a therapeutic dose and at a low dose, per European Union guidelines, met their primary endpoints.
The phase 3 study involved 254 patients who were scheduled to undergo chemotherapy for the treatment of breast cancer. The patients were randomized to receive either the biosimilar candidate or the reference product 24 hours after the administration of myelosuppressive chemotherapy. USV reports that its product demonstrated comparable safety and efficacy to the reference drug, and that the incidence of adverse events was comparable between the 2 treatment groups.
As of August 4, 3 other pegfilgrastim candidates were under review by the Committee for Medicinal Products for Human Use (CHMP). However, pegfilgrastim biosimilars have had difficulty reaching approval for the European marketplace; earlier this month, Biocon withdrew its application for a pegfilgrastim biosimilar as the company’s manufacturing facility awaits re-inspection. In January, Sandoz withdrew its application for a marketing authorization for its product, Zioxtenzo, telling the European Medicines Agency (EMA) that it would not be able to provide the additional data that the agency had requested within the allowed timeframe. In 2016, Gedeon Richter withdrew its applications for authorization to market its pegfilgrastim candidate as 2 products, Efgratin and Cavoley, after the CHMP issued a negative provisional opinion.
Biosimilars of pegfilgrastim have not fared much better in the US regulatory sphere. Sandoz’s drug was rejected by the FDA in 2016, and Coherus received a complete response letter for its attempt at a biosimilar, CHS-1701, in June. Coherus has vowed to continue development of the drug, and is currently engaged in patent litigation with Amgen, maker of Neulasta.
Two additional proposed biosimilars are currently under FDA review; Apotex announced that the FDA had accepted its filing for its product in 2014, but no regulatory action has yet been taken on the product. Biocon’s product also remains under FDA review, though it is unclear whether the issues with the company’s facility that prompted a withdrawal of its EMA application could impact the FDA’s verdict on the drug, which is expected by the Biosimilar User Fee Act date of October 9, 2017.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.